A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
for Non-small Cell Lung Cancer (NSCLC)
Drug: Durvalumab
38 locations incl. Daphne
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07361497·Phase 3·Recruiting